DOI: 10.1055/s-00000030

Der Klinikarzt


Iveson T, Donehower RC, Davidenko I et al.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Lancet Oncol 2014;
14: 1470-2045

Download Bibliographical Data

Search in: